According to the current analysis of Reports and Data, the global Hemoglobinopathies market was valued at USD 5.31 Billion in 2018 and is expected to reach USD 13.68 Billion by year 2027, at a CAGR of 10.2% from 2019-2027.
Hemoglobinopathies is a genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule. Hemoglobinopathy disorders include sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and various forms of thalassemia.
The growth of the hemoglobinopathies market is driven by the increasing prevalence of hemoglobinopathies in developed countries, high-level diseases, a variety of government support initiatives and NGO funding. Advanced diagnostic and therapeutic factors, favorable diagnostic and economical approaches such as genetic testing and developing rapid point of care diagnostic methods are other factors that drive the global hemoglobinopathy market. The hemoglobinopathies market is distributed mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). According to WHO, around 300,000 to 500,000 children born each year are affected by hemoglobin disorders. North America spearheaded the market in terms of revenue in 2018 due to rising R&D investments by the key players, promising reimbursement scenario, and presence of high-quality healthcare infrastructure.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2165
The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers. The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors. It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.
Key players in the market include
Alnylam Pharmaceuticals, Gamida Cell, Biogen Idec, AcceleronPharma, Sangamo BioSciences, Anthera Pharmaceuticals, Global Blood Therapeutics, Geetix Pharmaceuticals, Mast Therapeutics, Prolong Pharmaceuticals, Emmaus Medical, Celgene Corporation, Invenux, Optinova Ab, and HemaQuest Pharmaceuticals
Regional segmentation comprises of a current and forecast estimation of the market in the key geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers the scope of individual applications and types in each region. The report also covers details about production and consumption patterns, technological developments, revenue growth, market size, market share, key trends and demands influencing market growth in the region, and robust presence of key players in the region.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2165
Key players in the market include
Type (Revenue, USD Million; 2017–2027)
Therapy Type (Revenue, USD Million; 2017–2027)
Test Type (Revenue, USD Million; 2017–2027)
Regional analysis further covers a country-wise analysis to offer insights into key trends and demands in each major country that might affect the growth of the market in the region.
To know more about the report @ https://www.reportsanddata.com/report-detail/hemoglobinopathies-market
Key Features of the Global Hemoglobinopathies Market Report:
Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2165
Thank you for reading our report. Customization of this report is available according to the client’s needs. Please get in touch with us to know more about the customization feature and our team will ensure the report is tailored as per your requirements.
Browse More Reports :